Search

Your search keyword '"Rappold, Erica"' showing total 21 results
Start Over Author "Rappold, Erica"
21 results on '"Rappold, Erica"'

3. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)

Author

Sancho, Juan-Manuel, primary, Abrisqueta, Pau, additional, Kumar, Abhijeet, additional, Cordoba, Raul, additional, Tani, Monica, additional, Langmuir, Peter, additional, Rappold, Erica, additional, Liu, Teng, additional, and Lopez-Guillermo, Armando, additional

Published
2024
Full Text
View/download PDF

5. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

Author

Boyle, Frances M., Smith, Ian E., O’Shaughnessy, Joyce, Ejlertsen, Bent, Buzdar, Aman U., Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen I., Lindquist, Deborah, Amonkar, Mayur, Huang, Yingjie, Rappold, Erica, Williams, Lisa S., Wang-Silvanto, Jing, Kaneko, Tomomi, Finkelstein, Dianne M., and Goss, Paul E.

Published
2015
Full Text
View/download PDF

6. Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112)

Author

Sancho, Juan-Manuel, primary, Abrisqueta, Pau, additional, Kumar, Abhijeet, additional, Cordoba, Raul, additional, Tani, Monica, additional, Liu, Teng, additional, Rappold, Erica, additional, Langmuir, Peter, additional, and Lopez-Guillermo, Armando, additional

Published
2022
Full Text
View/download PDF

7. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

Author

Goss, Paul E, Smith, Ian E, O'Shaughnessy, Joyce, Ejlertsen, Bent, Kaufmann, Manfred, Boyle, Frances, Buzdar, Aman U, Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen I, Lindquist, Deborah, Chavarri-Guerra, Yanin, Aktan, Gursel, Rappold, Erica, Williams, Lisa S, and Finkelstein, Dianne M

Published
2013
Full Text
View/download PDF

9. A Phase 1 Study of Parsaclisib in Combination with Investigator Choice of Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma (CITADEL-112): Preliminary Safety Results

Author

Sancho, Juan-Manuel, primary, Lopez-Guillermo, Armando, additional, Abrisqueta, Pau, additional, Kumar, Abhijeet, additional, Cordoba, Raul, additional, Tani, Monica, additional, Zhao, Wanying, additional, Rappold, Erica, additional, Langmuir, Peter, additional, and Mims, Martha, additional

Published
2022
Full Text
View/download PDF

10. Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Author

Phillips, Tycel, primary, Avigdor, Abraham, additional, Gurion, Ronit, additional, Patti, Caterina, additional, Corradini, Paolo, additional, Tani, Monica, additional, Mehta, Amitkumar, additional, Lossos, Izidore S., additional, Zinzani, Pier Luigi Luigi, additional, Thieblemont, Catherine, additional, Jurczak, Wojciech, additional, Zheng, Fred, additional, Rappold, Erica, additional, Zhao, Wanying, additional, and Johnson, Peter, additional

Published
2021
Full Text
View/download PDF

12. Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Author

Phillips, Tycel J., primary, Corradini, Paolo, additional, Gurion, Ronit, additional, Patti, Caterina, additional, Tani, Monica, additional, Avigdor, Abraham, additional, Jurczak, Wojciech, additional, Mehta, Amitkumar, additional, Zinzani, Pier Luigi, additional, Lossos, Izidore S., additional, Thieblemont, Catherine, additional, Zheng, Fred, additional, Rappold, Erica, additional, Zhao, Wanying, additional, and Johnson, Peter, additional

Published
2020
Full Text
View/download PDF

14. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Author

Strasser-Weippl, Kathrin, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen, Lindquist, Deborah, Rappold, Erica, Finkelstein, Dianne D.M., Goss, Paul E, Horick, Nora, Smith, Ian, O'Shaughnessy, Joyce, Ejlertsen, Bent, Boyle, Frances, Buzdar, Aman, Fumoleau, Pierre, Gradishar, William, Strasser-Weippl, Kathrin, Martin, Miguel, Moy, Beverly, Piccart-Gebhart, Martine, Pritchard, Kathleen, Lindquist, Deborah, Rappold, Erica, Finkelstein, Dianne D.M., Goss, Paul E, Horick, Nora, Smith, Ian, O'Shaughnessy, Joyce, Ejlertsen, Bent, Boyle, Frances, Buzdar, Aman, Fumoleau, Pierre, and Gradishar, William

Abstract

Introduction: Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described. Methods: Using data from 1,260 patients randomized to placebo in the adjuvant TEACH trial, we report 10-year annual hazards of recurrence in HER2+ patients not treated with anti-HER2 therapy. Results: Disease-free survival (DFS) was 75% after 5 and 61% after 10years, respectively. Patients with HER2+hormone receptor-positive (HR+ (hormone receptor-positive); ER+ (estrogen receptor-positive) or PR+ (progesterone receptor-positive)) disease had a significantly better DFS than patients with HER2+HR- (ER-/PR-) disease (hazard ratio 0.72, P=0.02). This difference was explainable by a significantly higher hazard of recurrence in years 1 to 5 in HER2+HR- compared to HER2+HR+ patients, with a mean risk of recurrence of 9%/year for HR- versus 5%/year in HR+ patients (hazard ratio 0.59, P=0.002 for years 1 to 5). The high early risk of recurrence of HER2+HR- patients declined sharply over time, so that it was similar to that seen in HER2+HR+ patients in years 6 to 10 (hazard ratio 0.97, P=0.92 for years 6 to 10). Conclusions: Our results show that outcomes in HER2+ patients with early BC not receiving anti-HER2 therapy strongly depend on HR expression. The very high early risk of relapse seen in HER2+HR- patients is particularly relevant in health care settings with limited access to adjuvant anti-HER2 treatment. The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2+HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2015

15. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

Author

Boyle, Frances, Moy, Beverly, Finkelstein, Dianne D.M., Goss, Paul E, Smith, Ian I.E., O'Shaughnessy, Joyce, Ejlertsen, Bent, Buzdar, Aman, Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Piccart-Gebhart, Martine, Pritchard, Kathleen, Lindquist, Deborah, Amonkar, Mayur, Huang, Yingjie, Rappold, Erica, Williams, Lisa L.S., Wang-Silvanto, Jing, Kaneko, Tomomi, Boyle, Frances, Moy, Beverly, Finkelstein, Dianne D.M., Goss, Paul E, Smith, Ian I.E., O'Shaughnessy, Joyce, Ejlertsen, Bent, Buzdar, Aman, Fumoleau, Pierre, Gradishar, William, Martin, Miguel, Piccart-Gebhart, Martine, Pritchard, Kathleen, Lindquist, Deborah, Amonkar, Mayur, Huang, Yingjie, Rappold, Erica, Williams, Lisa L.S., Wang-Silvanto, Jing, and Kaneko, Tomomi

Abstract

Background To evaluate health related quality of life (HRQOL) in TEACH, a phase III randomized placebo controlled trial of 12 months of adjuvant lapatinib in HER2 positive (HER2+) early breast cancer which demonstrated marginal benefit in disease-free survival. Methods Women on TEACH completed the Short Form 36-item health survey (version2; SF-36v2) at the baseline, six and 12 months after therapy initiation and six monthly thereafter. Mean changes were compared between treatment groups for two summary measures (Physical and Mental Component Summary scores; PCS and MCS) and eight domain measures (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health), and in patients discontinuing therapy. A five-point change was deemed a Minimally Clinically Important Difference (MCID). Response analysis compared the proportion of patients demonstrating a MCID in HRQOL, and a regression analysis identified predictors of worsening HRQOL. Findings 3074 (97%) subjects completed baseline SF-36v2. During the initial 12 months, summary SF-36v2 scores decreased in both arms but did not reach Minimally Clinically Important Difference (MCID) despite significant incidences of diarrhoea and rash in lapatinib treated patients. At six months, women receiving lapatinib had more significant reductions (p < 0.01 versus placebo) in social functioning. Early treatment discontinuations were more frequent on lapatinib (32% versus 18%), and were associated with more substantial decrements of HRQOL in both arms. For those discontinuing primarily due to adverse events, decrements in HRQOL reached MCID in Mental Summary scores (MCS) only. Lower baseline HRQOL was a significant predictor of worsening HRQOL (p < 0.05). Interpretation Despite frequent but usually mild toxicities, adjuvant lapatinib is not associated with clinically significant decreases in overall HRQOL. These placebo-controlled results may also help to inform physici, SCOPUS: cp.j, info:eu-repo/semantics/published

Published
2015

17. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Author

Strasser-Weippl, Kathrin, primary, Horick, Nora, additional, Smith, Ian E, additional, O’Shaughnessy, Joyce, additional, Ejlertsen, Bent, additional, Boyle, Frances, additional, Buzdar, Aman U, additional, Fumoleau, Pierre, additional, Gradishar, William, additional, Martin, Miguel, additional, Moy, Beverly, additional, Piccart-Gebhart, Martine, additional, Pritchard, Kathleen I, additional, Lindquist, Deborah, additional, Rappold, Erica, additional, Finkelstein, Dianne M, additional, and Goss, Paul E, additional

Published
2015
Full Text
View/download PDF

18. Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury

Author

Schaid, Daniel J., primary, Spraggs, Colin F., additional, McDonnell, Shannon K., additional, Parham, Laura R., additional, Cox, Charles J., additional, Ejlertsen, Bent, additional, Finkelstein, Dianne M., additional, Rappold, Erica, additional, Curran, Joan, additional, Cardon, Lon R., additional, and Goss, Paul E., additional

Published
2014
Full Text
View/download PDF

19. Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2–ve BC): Analysis of patients in the TEACH trial.

Author

Chavarri Guerra, Yanin, primary, Chan, Arlene, additional, Finkelstein, Dianne M., additional, Chan, Valorie F., additional, Harvey, Vernon J., additional, Lee, Keun Seok, additional, Jain, Minish Mahendra, additional, Petrakova, Katarina, additional, Raina, Vinod, additional, Xu, Binghe, additional, Gomez, Henry, additional, Rappold, Erica, additional, Kaneko, Tomomi, additional, Huang, Yingjie, additional, and Goss, Paul E., additional

Published
2013
Full Text
View/download PDF

20. MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non–small cell lung cancer (NSCLC).

Author

Blumenschein, George R., primary, Smit, Egbert F., additional, Planchard, David, additional, Kim, Dong-Wan, additional, Cadranel, Jacques, additional, De Pas, Tommaso, additional, Dunphy, Frank, additional, Udud, Katalin, additional, Ahn, Myung-Ju, additional, Hanna, Nasser H., additional, Kim, Joo-Hang, additional, Mazieres, Julien, additional, Kim, Sang-We, additional, Baas, Paul, additional, Rappold, Erica, additional, Redhu, Suman, additional, Bellew, Kevin M., additional, Streit, Michael R. W., additional, Wu, Frank S., additional, and Janne, Pasi A., additional

Published
2013
Full Text
View/download PDF

21. Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.

Author

Smith, Ian Edward, primary, Finkelstein, Dianne M, additional, O'Shaughnessy, Joyce, additional, Moy, Beverly, additional, Ejlertsen, Bent, additional, Kaufmann, Manfred, additional, Buzdar, Aman, additional, Fumoleau, Pierre, additional, Gradishar, William John, additional, Martin, Miguel, additional, Boyle, Frances, additional, Piccart-Gebhart, Martine J., additional, Pritchard, Kathleen I., additional, Lindquist, Deborah, additional, Rappold, Erica, additional, Williams, Lisa Simone, additional, Liedke, Pedro E.R., additional, Chavarri-Guerra, Yanin, additional, and Goss, Paul Edward, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results